Cybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMT
Portfolio Pulse from Lara Goldstein
The U.S. Patent and Trademark Office has granted a new patent to Cybin Inc. (NYSE:CYBN) for the composition of matter of deuterated 5-MeO-DMT analogs and their pharmaceutical compositions. This strengthens Cybin's position in the development of therapeutics for mental health conditions. The company's CEO, Doug Drysdale, sees this as a timely development considering their upcoming merger with Small Pharma (OTC:DMTTF). The combined intellectual property of the two companies will provide an opportunity to develop novel therapeutics for patients in need of improved treatment options.
September 05, 2023 | 6:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cybin Inc. has been granted a new patent, strengthening its position in the development of therapeutics for mental health conditions. The upcoming merger with Small Pharma is expected to boost its intellectual property portfolio.
The new patent grant and the upcoming merger with Small Pharma are likely to strengthen Cybin's position in the market, potentially leading to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Small Pharma is set to merge with Cybin Inc., a move that is expected to boost the combined company's intellectual property portfolio.
The upcoming merger with Cybin Inc. is likely to boost Small Pharma's position in the market, potentially leading to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80